A--Drug Manufacturing and Formulation Program (DMFP)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) NIDA, under the Department of Health and Human Services, has awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP). These awards have a maximum ordering value of $49,999,999.00 over a ten-year period. The awards were made on May 4, 2026.
Scope of Work
This program, identified by Product/Service Code AN11 (Health R&D Services; Health Care Services; Basic Research), focuses on drug manufacturing and formulation. The IDIQ contracts are designed to support research and development efforts in this critical area.
Contract & Timeline
- Type: Four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts
- Maximum Ordering Value: $49,999,999.00
- Ordering Period: May 4, 2026, through May 3, 2036
- Award Date: May 4, 2026
- Initial Task Orders: Concurrently, first task orders were issued to each awardee, effective May 4, 2026, through July 3, 2026, with a firm-fixed price totaling $5,000.00.
- Place of Performance: Albany, NY, United States
- Set-Aside: Not specified.
Additional Notes
This is an award notice for a significant long-term program aimed at advancing drug manufacturing and formulation capabilities.